Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

SCHLIEREN (Zurich), Switzerland, March 13, 2007 - Cytos Biotechnology AG (SWX:CYTN) reported today positive results from a phase IIa study with CYT003-QbG10, an immunotherapeutic product candidate for the treatment of allergic diseases. The study included 40 patients suffering from mild to moderate allergic rhinitis due to grass pollen allergy (hay fever). The trial investigated in a doubleblind setting the safety, tolerability and exploratory efficacy of two different formulations of CYT003-QbG10 monotherapy to placebo, and in an open-label setting a CYT003-QbG10 formulation comprising a low dose of grass pollen extract. Exploratory efficacy of CYT003-QbG10 was determined by assessing the allergic disease status of the patients before and after treatment by the conjunctival provocation test, yielding a symptom score ranging from 0 to 15 points.

All formulations of CYT003-QbG10 tested were safe and well tolerated. Treatment with CYT003-QbG10 monotherapy led to a significant (p<0.05) improvement of allergy symptoms in the conjunctival provocation test when compared to placebo. A reduction of the median symptom score from 9 points pre-treatment to 5 points post-treatment was achieved (for placebo: 9 points pre-treatment to 8 points post-treatment). For the formulation of CYT003-QbG10 plus grass pollen extract, the median symptom score was reduced from 9 points pre-treatment to 4 points post-treatment, whereas for the formulation of CYT003-QbG10 plus alum, no significant reduction was observed when compared to placebo.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: "These results mark a further important milestone in the development of CYT003-QbG10 monotherapy and confirm prior open-label observations of efficacy of this product in a double-blind, placebo-controlled setting. At this stage, we are assessing various parameters of this promising Immunodrug™ candidate such as different formulations,
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/16/2014)... 2014 A study led by St. ... chemotherapy dose threshold below which male childhood cancer survivors ... appears in September 17 edition of the journal ... are at highest risk for reduced sperm production as ... of pre-treatment fertility preservation methods such as sperm banking. ...
(Date:9/16/2014)... Ill. , Sept. 16, 2014 ... new director of Business Communications & Advocacy, Urology ... President, Business Communications & Advocacy Margaret Long. In this ... commitment to urology to patient and advocacy organizations, ... teams on key strategic initiatives. Noland,s appointment is ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Dan ... GWM Products, LLC, manufacturer of the RTD ® ... plan to expand its sales presence in the U.S. ... hiring and training direct field sales representatives in new ... The company plans to add up to 20 sales ...
Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2
... Va., Oct. 30 CEL-SCI Corporation,(Amex: CVM ) ... at the Rodman & Renshaw 9th Annual Healthcare Conference ... 5-7, 2007. The presentation,will be focused on its Phase ... product seeking to become a new first line standard ...
... the Potential ... INDIANAPOLIS and MUMBAI, India, Oct. 30 Eli,Lilly and Company ... into an,agreement with Glenmark Pharmaceuticals S.A. (GPSA) a wholly owned,subsidiary ... agreement, Lilly will acquire the rights to a portfolio of ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 3Lilly and Glenmark Pharmaceuticals Announce License Agreement 4Lilly and Glenmark Pharmaceuticals Announce License Agreement 5
(Date:9/17/2014)... ATLANTA, GA (PRWEB) September 17, 2014 ... Contact Center software, has launched Presence Suite 10.0, ... journey and improve the customer experience. , The ... autonomy and flexibility. Now supervisors can get a ... and understand who is contributing most and who ...
(Date:9/16/2014)... 17, 2014 Recently, BamboofloorChina.com, the popular ... new assortment of strand woven bamboo floors ... launched a big promotion for the new items; the ... , Autumn is a great shopping season. Therefore, BamboofloorChina.com ... old and new customers. All practical items offered by ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 Dog Food ... dog owners the true poisonous ingredients in most commercial dog ... recipes has caught the attention of Shane Michaels, prompting an ... just as much of a family member as any other ... dog dies earlier than it should due to poor diet” ...
(Date:9/16/2014)... Retinol is favored by a majority of dermatologists and ... so many benefits - it is one of those amazing ... Sublime Beauty . "Healthy skin is our goal, and Retinol ... Retinol Serum with Vitamin C is a non-irritating, silky serum ... Retinol Serum with Vitamin C is now 30% ...
(Date:9/16/2014)... City, UT (PRWEB) September 16, 2014 ... Benefits Solution, published new information on transitioning employees ... Zane Benefits, with the Affordable Care Act (ACA) ... businesses will be steering some or all of ... as no surprise. With guaranteed issue plans, coverage ...
Breaking Medicine News(10 mins):Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:Dog Food Secrets: Review Exposes Andrew Lewis’ Guide to Happier, Healthier Dogs with Homemade Dog Food 2Health News:Retinol, the Gold Standard in Skin Care, Available in a Serum with Vitamin C from Sublime Beauty®; Now 30% Off 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2
... Walk on the Capitol,is proud to announce Caitlin Van ... guest speaker for our National obesity awareness event,in Washington, ... Capitol is a,history-making awareness event that will gather thousands ... the obesity epidemic and,the need for expanded efforts in ...
... 2 ,Dawning Technologies, Inc. (Dawning) and Medical Automation ... joint project to leverage their,product synergies and create ... project will focus on the seamless integration of ... RALS(R)-,Plus POC Data Management solutions. RALS-Plus is a ...
... Merger, CHICAGO, June 2 Allscripts, the ... that,physicians use to improve healthcare, announced today that ... Act of,1976, with respect to the merger agreement ... Healthcare to form Allscripts-Misys Healthcare,Solutions, Inc., has expired., ...
... MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure ... company developing,high-value human plasma-derived protein products for ... quarter results., Financing, As a ... to-date from key,shareholders to exercise their Series ...
... care deserves more funding for estimated 2.5 million displaced ... removed from their homes due to mistreatment have fewer ... kinship care -- than if they,re placed in foster ... by researchers at Children,s Hospital of Philadelphia, looked at ...
... are similar to the type diagnosed in Sen. Edward ... experimental cancer vaccine is showing promise against the same ... Kennedy, researchers are reporting. , The vaccine, when given ... with glioblastoma multiforme tumors. Kennedy was diagnosed last month ...
Cached Medicine News:Health News:Television Star Caitlin Van Zandt Signs-on as Special Guest Speaker for National Obesity Awareness Event in Washington, DC, on June 17 2Health News:Dawning Technologies, Inc. and Medical Automation Systems, Inc. to Develop a Business Partnership 2Health News:Antitrust Waiting Period Expires on Allscripts-Misys Merger Agreement 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 2Health News:Haemacure Reports on Financing Progress and Second Quarter Results 3Health News:Kids Living With Relatives Have Fewer Problems Than Those in Foster Homes 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3
... Predictor Test is a qualitative, one-step, ... Follicle Stimulating Hormone (FSH) in urine ... changes related to the symptoms associated ... The FHS Menopause Predictor Test is ...
Serim PyloriTek Test Kit detects urease activity in gastric biopsy specimens for the presumptive identification of an Helicobacter pylori infection....
Immunoassay for rapid, qualitative detection of IgG antibodies specific to Helicobacter pylori in whole blood....
... The Accutest H. pylori ... test for the qualitative detection ... Helicobacter pylori in human whole ... intended as an aid in ...
Medicine Products: